Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | SRPK1 | Q96SB4 | 14/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205424 | 0.89 | ACHE (0.56) | BCHEACHEBACE1MAPT | |
| SCHEMBL6208348 | 0.87 | EEF2K (0.37) | BCHEACHEBACE1SRPK1KDM4E | |
| SCHEMBL6404616 | 0.87 | BCHE (0.37) | BCHEACHEBACE1MAPT | |
| SCHEMBL6206805 | 0.85 | BCHE (0.39) | BCHEACHEBACE1ALDH1A1LMNA | |
| SCHEMBL6207211 | 0.85 | BCHE (0.37) | BCHEACHEBACE1KDM4E | |
| SCHEMBL6206922 | 0.84 | BCHE (0.37) | BCHEACHEBACE1KDM4EALDH1A1 | |
| SCHEMBL6230497 | 0.82 | KCNH2 (0.38) | BCHEACHEBACE1KDM4EALDH1A1 | |
| SCHEMBL6206929 | 0.80 | CDC7 (0.45) | — | |
| SCHEMBL6406191 | 0.78 | ALDH1A1 (0.38) | KDM4EALDH1A1LMNA | |
| SCHEMBL6208052 | 0.78 | HRH3 (0.34) | BCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | BCHE 3693/4885ACHE 2974/4885BACE1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.